NCT01329068

Brief Summary

Carriers of a BRCA mutation have a significantly increased risk to develop breast cancer in the course of their lives . They face a difficult choice: either a preventive removal of the breast(s) or an intensive inspection process. After primary treatment of breast cancer, patients will be followed for 5-10 years to diagnose recurrence or a new primary tumor in an early stage; to support the patient during hormonal treatment; to educate the patient about risk factors and healthy life style; and to provide psychosocial support. Currently, follow-up of breast cancer patients and surveillance of BRCA mutation carriers is offered in regular, one-to-one medical visits. Experience shows that in an individual visit it is often not possible to give all aspects that are important, enough attention. The group medical consultation (GMC) is a new form of medical visits where the physician or nurse practitioner performs a series of one-to-one consultations in the presence of 8 to10 other patients. A social worker accompanies this process. Patients in group consultations may gather more information because they learn from each other and there is relatively more time compared to a regular consultation. Research shows that both patients and caregivers are more satisfied with care after a group consultation compared to individual visits. After a GMC the participants from the breast cancer GMCs will be provided with a dedicated iPad for 3 months. Using this iPad, patients can contact the women they have met during the GMC as well as health care professionals by several communication channels, including virtual group meetings. This approach provides a unique combination of both social support and professional education concerning survivorship in an e-health environment.However, it is also known that group sessions may be counterproductive for some patients, for example because they are frightened by the stories of others. The goal of this study is to examine whether group visits (in combination with dedicated iPads) are beneficial to women with a BRCA mutation and for patients in follow-up after breast cancer.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
320

participants targeted

Target at P75+ for not_applicable breast-cancer

Timeline
Completed

Started Apr 2011

Typical duration for not_applicable breast-cancer

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 31, 2011

Completed
1 day until next milestone

Study Start

First participant enrolled

April 1, 2011

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 5, 2011

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2014

Completed
Last Updated

January 20, 2012

Status Verified

October 1, 2011

Enrollment Period

2.8 years

First QC Date

March 31, 2011

Last Update Submit

January 19, 2012

Conditions

Keywords

breast cancer

Outcome Measures

Primary Outcomes (1)

  • Psychological distress (SCL-90) and empowerment (Cancer Empowerment Questionnaire)

    BRCA mutation carriers: Baseline (1 week before the (group) medical visit) and 1 week and three months after the (group) medical visit.

Secondary Outcomes (1)

  • Questionnaires for patients and health care professionals, observations and user measurements of the iPads.

    BRCA mutation carriers: Baseline (1 week before the (group) medical visit) and 1 week and three months after the (group) medical visit.

Study Arms (2)

Individual consult

ACTIVE COMPARATOR

regular individual consult

Behavioral: individual consult

group medical consult

ACTIVE COMPARATOR

regular group medical consult

Behavioral: group medical consult

Interventions

regular individual consultations

Individual consult

group medical consult

group medical consult

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants: patients in follow-up after breast cancer
  • Women ≥ 18 years of age with histologically proven breast cancer.
  • Primary treatment (surgery, radiotherapy, chemotherapy) completed maximally 5 years ago.
  • Participants: women with a BRCA mutation
  • Women ≥ 25 years of age with a proven BRCA1 or BRCA2 mutation.

You may not qualify if:

  • Participants: patients in follow-up after breast cancer
  • Metastatic breast cancer
  • Currently involved in a diagnostic work-up because of a suspicion of breast cancer, either primary or metastatic.
  • A history of prophylactic mastectomy.
  • Current psychiatric disease precluding consultations in a group.
  • Insufficient command of the Dutch language to be able to follow a group discussion and/or to fill out a Dutch questionnaire
  • Participants: women with a BRCA mutation
  • Metastatic breast cancer
  • Currently involved in a diagnostic work-up because of a suspicion of breast cancer, either primary or metastatic.
  • A history of prophylactic mastectomy.
  • Current psychiatric disease precluding consultations in a group.
  • Insufficient command of the Dutch language to be able to follow a group discussion and/or to fill out a Dutch questionnaire

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Radboud University Nijmegen Medical Centre

Nijmegen, Gelderland, 6500 HB, Netherlands

RECRUITING

Related Publications (1)

  • Visser A, Prins JB, Hoogerbrugge N, van Laarhoven HW. Group medical visits in the follow-up of women with a BRCA mutation: design of a randomized controlled trial. BMC Womens Health. 2011 Aug 24;11:39. doi: 10.1186/1472-6874-11-39.

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • H.W.M. van Laarhoven, Md PhD

    Radboud University Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 31, 2011

First Posted

April 5, 2011

Study Start

April 1, 2011

Primary Completion

February 1, 2014

Study Completion

February 1, 2014

Last Updated

January 20, 2012

Record last verified: 2011-10

Locations